logo
welcome
Investor's Business Daily

Investor's Business Daily

Eli Lilly lowers guidance for December quarter amid slower-than-expected sales for weight loss drugs

Investor's Business Daily
Summary
Nutrition label

79% Informative

Eli Lilly ( LLY ) lowered guidance for its December quarter amid slower-than-expected sales for its Zepbound and Mounjaro weight loss drugs.

The Indianapolis -based company said it expects revenue of about $13.5 billion , below consensus estimates.

Eli Lilly stock fell more than 7% to 741.22 .

VR Score

85

Informative language

92

Neutral language

42

Article tone

formal

Language

English

Language complexity

37

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

detected

Known propaganda techniques

not detected

Time-value

short-lived

Affiliate links

no affiliate links